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The aim of this study was to evaluate the efficacy and toxicity of a concurrent chemoradiotherapy using docetaxel, cisplatin and 5-
fluorouracil (5-FU) (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). In total, 19
patients with previously untreated stage III–IV SCCHN were entered onto this trial. Patients received two cycles of chemotherapy.
Cycles were repeated every 4 weeks. The starting doses (dose level 1) were docetaxel 60mgm
 2, cisplatin 70mgm
 2, and 5-day
continuous infusion of 5-FU 600mgm
 2day
 1. Radiation was targeted to begin on the first day of chemotherapy, day 1. The total
radiation dose to the primary tumour site and neck lymph nodes was between 63.0 and 74.0Gy. At least three patients were
examined at each dose level before advancing to the next level. The maximum-tolerated dose (MTD) of this regimen was docetaxel
60mgm
 2, cisplatin 60mgm
 2 and 5-FU 600mgm
 2day
 1. The main toxicities were mucositis (grade 3 and 4, 79%),
leukocytopenia (grade 3 and 4, 53%), neutropenia (grade 3 and 4, 42%), anaemia (grade 3, 16%), liver dysfunction (grade 3, 11%) and
renal dysfunction (grade 2, 11%). The overall response rate was 100%, including 84% complete responses (CRs). This concurrent
chemoradiotherapy with TPF was safe and well tolerated. The high CR rate justifies further evaluation of this chemoradiotherapy
modality in advanced SCCHN patients.
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In the majority of patients with squamous cell carcinoma of the
head and neck (SCCHN), the disease is locally advanced at
presentation, and the 3- to 5-year survival rates remain below 30%
(Veterans Affairs Laryngeal Cancer Study Group, 1991; Dimery
and Hong, 1993; Vokes et al, 1993; Paccagnella et al, 1994; Lefebvre
et al, 1996; Merlano et al, 1996). During the past 10 years,
combined-modality approaches have been developed in an effort
to enhance locoreginal disease control, reduce distant metastatic
spread and improve survival in patients with locally advanced or
inoperable SCCHN. Randomised trials have shown that chemor-
adiotherapy and induction chemotherapy are effective in preser-
ving organ function in a subset of patients by reducing the need for
surgery of the primary tumour site in patients with resectable
disease, and improving survival in patients with unresectable
disease (Veterans Affairs Laryngeal Cancer Study Group, 1991;
Paccagnella et al, 1994; Lefebvre et al, 1996; Merlano et al, 1996;
Calais et al, 1999). The standard induction regimen consists of
cisplatin and continuous-infusion 5-fluorouracil (5-FU) (PF) and
has been associated with a complete response (CR) rate of about
30% in randomised trials (Kish et al, 1985; Veterans Affairs
Laryngeal Cancer Study Group, 1991; Lefebvre et al, 1996). The
survival of patients with stage III and IV disease remains poor
despite these improvements.
Docetaxel is a new agent that has demonstrated significant
activity against SCCHN. A number of studies have explored the
combination of docetaxel, cisplatin and 5-FU (TPF) in SCCHN,
with promising results. The overall response rate with the three
drugs in previously untreated, advanced SCCHN was approxi-
mately 64–93% (Janinis et al, 1997; Colevas et al, 1999; Schrijvers
et al, 1999a). Different investigators also examined the feasibility of
combination of docetaxel and radiotherapy. Koukourakis et al
(1999) tested in a phase I setting the combination of docetaxel,
irinotecan and conventional radiotherapy. With combination of
weekly docetaxel 20mgm
 2 and irinotecan 25mgm
 2, the overall
response rate in 12 patients with locally advanced head and neck
cancer was 100%, with 75% CRs.
Here, we report the results of aggressive concurrent chemor-
adiotherapy with TPF in patients with locally advanced SCCHN. The
main end points of this study were the toxicity of this concurrent
chemoradiotherapy and preliminary assessment of the efficacy of
this regimen in patients with advanced and untreated SCCHN.
PATIENTS AND METHODS
Patient population
Patients were selected if they had histologically or cytologically
confirmed SCCHN, at least one unidimensionally measurable
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llesion, and stage III or IV disease without evidence of distant
metastases. Patients with primary sites in the nasopharynx,
mesopharynx, hypopharynx, larynx, oral cavity or paranasal sinus
were eligible. Patients who had received previous chemotherapy,
radiotherapy or surgery were excluded. Patients were ineligible if
they had another cancer.
Patients were required to be from 20 to 75 years of age and have
an Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0 or 1, life expectancy of at least 3 months, a WBC
count of X4000cellsml
 1, an absolute neutrophil count (ANC) of
X2000cellsml
 1, a platelet count of X100000ml
 1, a haemoglobin
level of X9.5gdl
 1, AST, ALT and alkaline phosphatase levels
below 2.5 times the upper limit of normal (ULN), total bilirubin
and creatinine levels below than 1.5 times ULN, a BUN level below
the ULN and a 24-h creatinine clearance rate of more than
60mlmin
 1. Patients with significant cardiac arrhythmia or heart
failure were ineligible. All patients provided written informed
consent prior to enrollment in the study.
Treatment schedule and dose escalation
Before this trial, we had carried out phase I trial of combined
induction chemotherapy with docetaxel, cisplatin, and 5-FU for
patients with locally advanced SCCHN (Tsukuda et al, 2003). The
maximum-tolerated dose (MTD) of the regimen was docetaxel
70mgm
 2 (day 1), cisplatin 70mgm
 2 (day 4), and 5-FU
750mgm
 2day
 1 (days 1–5), and the regimen was safe and
generally well tolerated and demonstrated good efficacy in patients
with locally advanced SCCHN. Based on that previous study, we
decided the initial dose level of this study. This study was
concurrent chemoradiotherapy, and toxicities, such as mucositis,
leukocytopenia and neutropenia, were thought to be more severe
than induction chemotherapy, so that we reduced the initial dose
level of docetaxel and 5-FU.
Table 1 shows the dose-escalation levels. The initial dose level
(level 1) was docetaxel 60mgm
 2 (day 1), cisplatin 70mgm
 2 (day
4) and 5-FU 600mgm
 2day
 1 (days 1–5). The administration
schedule is shown in Figure 1. Docetaxel was administered
intravenously over 1h on day 1. More than 1h after completion
of the docetaxel infusion, 5-FU on days 1–5 was delivered by
continuous intravenous infusion with 3.5l of NS per day. Cisplatin
was administered intravenously on day 4. Patients received
ramosetron 0.3mg and dexamethasone 8mg intravenously on
days 4–8 of chemotherapy. Two cycles of chemotherapy were
repeated every 4 weeks.
Radiotherapy (1.8–2.0Gyfraction
 1day
 1), administered 5
days per week, was delivered to the primary tumour site and neck
and was targeted to begin on the first day of chemotherapy, day 1.
The mean total dose to the primary tumour site and neck lymph
nodes was 67.8Gy (range, 63.0–74.0Gy). Every effort was made to
continue the radiation on schedule. Subcutaneous G-CSF
100mgbody
 1day
 1 was injected if the neutrophil count was less
than 1000cellsul
 1 after chemotherapy.
Retreatment on day 29 required ANC of X2000cellsml
 1,a
platelet count of X100000ml
 1, a haemoglobin level of
X9.5gdl
 1, AST, ALT and alkaline phosphatase levels below 2.5
times the ULN, a 24-h creatinine clearance rate of more than
50mlmin
 1 and resolution of all other nonhaematological
toxicities (except alopecia, musculoskeletal pain and fatigue) to
be baseline or less than grade 1. If there were some toxicities as
above, cycle 2 chemotherapy was delayed, and if the delay
exceeded 14 days, the patient was removed from the study.
Patients were monitored for toxicity (medical interview, physical
examination and complete blood cell counts) during treatment.
Blood and urine chemistries were performed 2 or 3 times a week.
The MTD was defined as follows. If all three patients at any dose
level experienced a dose-limiting toxicity (DLT), subsequent
patients were treated at the next lower dose level. If two out of
three experienced a DLT, the prior dose level was defined as the
MTD. If one out of three patients experienced a DLT, three
additional patients were added at that dose level. If more than
three out of six experienced a DLT, then the prior dose level was
defined as the MTD. If less than three out of six experienced a DLT,
subsequent patients were treated at the next higher dose level. If
none of three patients experienced a DLT, subsequent patients
were treated at the next higher dose level.
Toxicity assessment
Toxicity was assessed once per cycle according to the 1998
National Cancer Institute Common Toxicity Criteria, version 2.0.
Resolution of effects such as myelosuppression, mucositis, fever
(438.01C) and other disorders was required prior to initiating the
second treatment cycle. A DLT was defined as grade 4 mucositis
that interrupts treatment for over 2 weeks, grade 4 thrombocyto-
penia, grade 2 nephrotoxicity, or grade 3 or 4 nonhaematologic
toxicity, excluding alopecia, nausea, vomiting, anorexia and
fatigue. In addition, grade 4 neutropenia, which was predicted to
occur in most patients, was not considered a DLT, because these
toxicities were clinically able to be managed by G-CSF support.
Clinical response and further treatment
The clinical response was assessed for each patient according to
the combined findings of CT, MRI and ultrasonic examinations at
3 weeks after the end of the chemoradiation therapy. The
definitions of CR, partial response (PR), no change (NC) and
progressive disease (PD) were based on the standard definitions
established by the WHO (1979). Clinical responses to this
Table 1 Dose levels in phase I trial of concurrent chemoradiotherapy
docetaxel/cisplatin/5-fluorouracil in SCCHN
Dose (mgm
 2day
 1)
Dose level
Docetaxel
(day 1)
Cisplatin
(day 4)
5-Fluorouracil
(days 1–5)
2 70 70 600
1
a 60 70 600
0 60 60 600
 1 50 60 600
aStarting dose level. Courses were repeated every 4 weeks.
Administration schedule
First cycle Second cycle
Irradiation: 63.0−74.0 Gy
Day 12
DOC CDDP
5-FU 120 h continuous i.v.
345 2 8 2 9
Figure 1 Administration schedule of docetaxel (DOC), cisplatin
(CDDP), and 5-fluorouracil (5-FU) in phase I study of patients with
advanced squamous cell carcinoma of the head and neck. i.v.¼intravenous
infusion.
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lchemoradiation therapy were confirmed by biopsies of the primary
site in all cases. In the case of N1–3 lymph node disease, fine
needle aspiration cytology of the neck lymph nodes was
performed. Responses at the primary site and the regional nodes
were scored separately, and the overall response was based on the
worst of the two responses. Surgery of the primary tumour site was
recommended for operable patients with resectable disease, who
failed to achieve CR after the end of the chemoradiation therapy.
Surgery was carried out routinely 4–6 weeks after the end of the
chemoradiation therapy.
RESULTS
Patients
A total of 19 patients were entered in this trial between July 2002
and February 2003. The characteristics of the population are listed
in Table 2. In all, 16 patients were males and three females, and the
average age was 60.0 years (range, 50–75 years). The PS (ECOG)
was 0 in 14 patients and 1 in five patients. The primary disease
sites were the nasopharynx (n¼3), oropharynx (n¼6), hypo-
pharynx (n¼4), larynx (n¼3), oral cavity (n¼2) and paranasal
sinus (n¼1). Eight patients had stage III disease, and the
remaining 11 patients were stage IV. Nine patients (47%) had N2
(n¼8) or N3 (n¼1) status before treatment, and seven patients
had N0 status.
Toxicity
Table 3 shows the grade 3–4 toxicities and DLTs that occurred at
each dose level. At level 1, all three patients experienced a DLT:
grade 4 mucositis that interrupted the radiation therapy for over 2
weeks in one patient, grade 3 anaemia in one, grade 3 elevation of
the AST level in one and grade 2 elevation of creatinine in one.
Next, patients were treated at level 0, and one of three patients
experienced a DLT; thus, three additional patients were added at
level 0. Three of six experienced a DLT: grade 3 anaemia in two
patients, grade 3 ALT elevation in one and grade 2 elevation of
creatinine in one. Thus, the doses used at level 0 were deemed the
MTDs of the regimen (i.e., docetaxel 60mgm
 2, cisplatin
60mgm
 2 and 5-FU 600mgm
 2day
 1). Additional patients were
entered at levels 0 and  1.
All 19 patients were assessable for toxicity. Mucositis was the
most common adverse effect observed, with grade 3 (n¼7) and
grade 4 (n¼8) mucositis observed in 79% (15 out of 19) of the
patients, and grade 4 mucositis that interrupted the radiation
therapy for over 2 weeks was observed in one patient at level 1.
Grade 3 (n¼8) and grade 4 (n¼2) leukocytopenia were observed
in 53% (10 out of 19) of the patients, and grade 3 (n¼6) and grade
4( n¼2) neutropenia were observed in 42% (8 out of 19). Grade 3
anaemia was observed in three patients, grade 3 ALT and AST
elevation in two, grade 3 thrombocytopenia in one and grade 2
creatinine elevation in one.
Responses
At 3 weeks following completion of the chemoradiotherapy, all
patients underwent biopsies of the primary tumour and/or fine
needle aspiration cytology with ultrasound technique of neck
lesions to determine the pathological response. As can be seen in
Table 4, the overall clinical response rate was 100% (19 out of 19)
and the pathological CR was 84% (16 out of 19). The primary site
CR was 89% (17 out of 19) and metastatic lymph node CR was 75%
(nine out of 12). After the chemoradiation therapy, there were
three PR patients. A patient with oral cavity cancer (T4N2c)
assigned to dose level 0 had PR at both the primary site and
metastatic lymph node. A patient with hypopharynx cancer
(T3N2c) in the level  1 had CR at the primary site and PR at
the metastatic lymph node. These two patients underwent surgery.
One patient with cancer of the hypopharynx (T4N2c) in level  1,
with metastatic retropharyngeal lymph nodes, had PR at
the primary site and metastatic lymph node, and he refused
surgery and received oral 5-FU (TS-1; 100mgday
 1) (Inuyama
et al, 2001).
Table 2 Baseline patient characteristics
Dose level
Patient characteristic
1
(n¼3)
0
(n¼8)
 1
(n¼8)
Total
(n¼19)
Male:female ratio 2:1 7:1 7:1 16:3
Age (years)
Average 66.7 55.8 61.6 60.0
Range (56–73) (50–66) (50–75) (50–75)
Performance status, no. of patients
0 2661 4
1 122 5
Primary site, no. of patients
Nasopharynx 1 1 1 3
Oropharynx 0 4 2 6
Hypopharynx 1 1 2 4
Larynx 1 0 2 3
Oral cavity 0 2 0 2
Paranasal sinus 0 0 1 1
Stage, no. of patients
III 1 3 4 8
IVA 2 4 4 10
IVB 0 1 0 1
Table 3 No. of patients with grade 3–4 toxicities and dose-limiting toxicities (DLTs)
Dose level
1( n¼3) 0 (n¼8)  1( n¼8) Total (n¼19)
Grade 3 4 3 4 3 4 3 4
Leukocytopenia 2 1 5 1 1 0 8 2
Neutropenia 1 1 4 1 1 0 6 2
Anaemia 1 0 2 0 0 0 3 0
Thrombocytopenia 1 0 0 0 0 0 1 0
Elevated AST, ALT levels 1 0 1 0 0 0 2 0
Elevated creatinine level 1
a 01
a 00 02
a 0
Mucositis 1 2 (1
b)5 3 1 3 7 8 ( 1
b)
aGrade 2 renal toxicity (DLT).
bGrade 4 mucositis that interrupts radiation therapy for over 2 weeks (DLT).
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lWith a median follow-up of 8 months and a range 3–11 months
as of July 2003, all 19 patients were alive and 18 patients had no
evidence of disease.
DISCUSSION
Multiple studies have demonstrated chemotherapy and radiation
therapy to be highly effective in increasing the survival of patients
with unresectable disease. Concurrent chemoradiotherapy
and induction chemotherapy have been established as an
appropriate standard of care for many patients with locally
advanced SCCHN.
The present study was designed to establish the MTD, safety and
efficacy of concurrent chemoradiotherapy, including docetaxel,
cisplatin and 5-FU in patients with locally advanced SCCHN. The
MTD was identified as docetaxel 60mgm
 2, cisplatin 60mgm
 2
and 5-FU 600mgm
 2day
 1. The regimen was generally well
tolerated and resulted in a high overall response rate of 100% and
CR rate of 84%.
Many studies have explored the PF chemotherapy followed by
radiation in SCCHN. The most comparable phase III trial of PF
chemotherapy followed by radiation was the European Organiza-
tion for Research and Treatment of Cancer (EORTC) Hypopharynx
Trial (Lefebvre et al, 1996). In the EORTC trial, patients were
treated with chemotherapy consisting of cisplatin 100mgm
 2 on
day 1 and 5-FU 1000mgm
 2day
 1 on days 1–5 every 4 weeks for
three cycles, and afterwards they were treated with irradiation
(70Gy). In this trial, 51% showed a clinical CR, and they showed
that PF chemotherapy followed by radiation was effective in
increasing the overall survival in unresectable disease, compared
with radiotherapy alone. Using PF, Taylor et al (1994) compared
concurrent chemoradiotherapy and chemotherapy followed by
radiation for toxicity and efficacy in patients with SCCHN. This
was a randomised trial between cisplatin 60mgm
 2 on day 1 plus
5-FU 800mgm
 2 on days 1–5 plus radiation 2Gy on days 1–5,
repeated every other week for seven cycles, vs cisplatin 100mgm
 2
on day 1 plus 5-FU 1.0gm
 2 on days 1–5, repeated every 3 weeks
for three cycles, followed by 70Gy of radiation for 7–8 weeks.
After all treatments, CR did not differ between the two groups
(52% in concurrent chemoradiotherapy and 50% in chemotherapy
followed by radiation). However, in terms of the overall response
rates, the concurrent chemoradiotherapy was better than the
chemotherapy followed by radiation (P¼0.003) (93% in con-
current chemoradiotherapy and 78% in chemotherapy followed by
radiation), and fewer patients with no change or progression after
concurrent treatment. Severe and worse toxic events were similar
between the treatment programmes. The concurrent chemora-
diotherapy with PF achieved improved disease control, predomi-
nantly of regional disease, compared with chemotherapy followed
by radiation.
Docetaxel was shown to be an effective agent in SCCHN in
multiple phase II studies (Forastiere et al, 1993, 1994; Catimel et al,
1994; Fujii et al, 1995; Couteau et al, 1996; Dreyfuss et al, 1996). Its
mechanism of action and side effects are different from both
cisplatin and 5-FU. Myelotoxicity is the DLT for the taxanes,
whereas myelotoxicity of PF is mild.
Different investigators also examined the combination of
docetaxel and radiotherapy. Mauer et al (1998) showed that it
was possible to combine doses of docetaxel up to
20mgm
 2week
 1 with conventional radiotherapy of 1.8–
2.0Gyday
 1 to a total dose of 60Gy in patients irradiated at the
thorax. Toxicity was mild, with oesophagitis and neutropenia as
dose-limiting toxicities.
Some studies explored combination of docetaxel and PF for
treatment of advanced SCCHN. Schrijvers et al (1999b) used
cisplatin 75 or 100mgm
 2, docetaxel 75mgm
 2 and 5-day
continuous infusion of 5-FU 750mgm
 2day
 1. The overall
response rate was 80%, none of which were CRs. Janinis et al
(2001) reported a 90% overall response rate and 20% CR rate with
cisplatin 40mgm
 2day
 1 for 2 days, docetaxel 80mgm
 2 and 3-
day continuous infusion of 5-FU 1000mgm
 2day
 1. Furthermore,
Posner et al (2001), using cisplatin 75 or 100mgm
 2, docetaxel
75mgm
 2 and 4-day continuous infusion of 5-FU
1000mgm
 2day
 1, reported an overall response rate of 93% and
CR rate of 40%.
A number of studies explored TPF chemotherapy followed by
radiation for SCCHN. Colevas et al (1999) studied combination
chemotherapy with docetaxel (60mgm
 2) on day 1, cisplatin
(31.25mgm
 2day
 1), 5-FU (700mgm
 2day
 1) and leucovorin
(500mgm
 2day
 1) on days 1–4 as a continuous infusion (TPFL-
4), followed by radiation for SCCHN. Cycles were repeated every
four weeks for three cycles. The overall RR was 93%, and the CR
rate was 63%. The major toxicities were mucositis, nausea,
neutropenia, anorexia; nephropathy, neuropathy and diarrhoea.
This study of concurrent chemoradiotherapy with TPF achieved an
overall RR of 100%. All patients underwent biopsy, and the
pathological CR rate was 84%. The response rates and pathological
CR rates of this concurrent chemoradiotherapy with TPF were;
better than those seen with TPF chemotherapy followed by
radiation, although comparisons between these studies are difficult
because of the variable drug doses.
In the present study, mucositis was the most common adverse
effect observed, with grade 3 (n¼7) and grade 4 (n¼8) mucositis
observed in 79% of patients. Calais et al (1999) showed the
incidence of grade 3 and 4 mucositis in the concurrent
chemoradiotherapy with PF was 71% and higher than with
radiotherapy only (39%). The incidence of mucositis was not so
different between concurrent chemoradiotherapy with TPF and PF.
Grade 3 (n¼8) and grade 4 (n¼2) leukocytopenia were observed
in 53% of the patients, grade 3 (n¼6) and grade 4 (n¼2)
neutropenia in 42%, grade 3 anaemia in three patients and grade 3
thrombocytopenia in one patient. There was a significant
difference in haematologic toxicity between concurrent chemor-
adiotherapy with TPF and PF, and TPF therapy results in an early,
brief and consistent neutropenia. Grade 4 mucositis that
interrupted radiation therapy for over 2 weeks was observed in
one patient at level 1, but all 19 patients were assessable for
toxicity. These findings suggest that the toxicity of the concurrent
chemoradiotherapy with TPF compares favourably with concur-
rent chemoradiotherapy with PF chemotherapy.
Before this trial, we had carried out phase I trial of combined
induction chemotherapy with docetaxel, cisplatin and 5-FU for
Table 4 Clinical response at each dose level, and by primary site and
metastatic lymph nodes
Dose level
(doses of
docetaxel/
cisplatin/5-FU)
No. of
evaluable
patients
Overall
response Site CR PR NC PD NE
1 3 CR 3 P 3
(60/70/600) N 2 1
08 C R 7 P 7 1
(60/60/600) PR 1 N 4 1 3
 1C R 6 P 7 1
(50/60/600) 8 PR 2 N 3 2 3
Total 19 CR 16 P 17 2
PR 3 N 9 3 7
P¼primary site; N¼metastatic lymph node; NE¼not evaluable because N0 at
baseline.
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lpatients with locally advanced SCCHN (Tsukuda et al, 2003). The
MTD of the regimen was docetaxel 70mgm
 2 (day 1), cisplatin
70mgm
 2 (day 4), and 5-FU 750mgm
 2day
 1 (days 1–5). Based
on that previous study, we decided the initial dose level of this
study. This study was concurrent chemoradiotherapy, and
toxicities, such as mucositis, leukocytopenia, neutropenia, were
thought to be more severe than induction chemotherapy; there-
fore, we reduced the initial dose level of docetaxel and 5-FU, and
the initial dose level (level 1) was decided to be docetaxel
60mgm
 2 (day 1), cisplatin 70mgm
 2 (day 4) and 5-FU
600mgm
 2day
 1 (days 1–5). This study was constructed as a
dose-escalation study but ended as a DE-escalation study. We
underestimated the toxicities of radiation.
This concurrent chemoradiotherapy with TPF showed major
antitumour activity with manageable toxicity as treatment of
SCCHN patients. The high CR rate justifies further evaluation of
this chemoradiotherapy combination. Based on the high response
rate shown in this study, we are conducting a randomised
comparison of concurrent chemotherapy with TPF vs concurrent
chemoradiotherapy with CDDP, 5-FU, methotrexate and leucovorin.
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